Novo Semaglutide EVOKE Failed: GLP-1 Brain Hypothesis Dead

The Failure

On November 24, 2025, Novo Nordisk announced that oral semaglutide failed both Phase 3 EVOKE and EVOKE+ trials in early-stage symptomatic Alzheimer’s disease. The results were published in The Lancet on May 30, 2026, and presented in detail at AAIC 2026. The numbers are brutal.

The primary endpoint was change in CDR-Sum of Boxes (CDR-SB) from baseline to Week 104. In EVOKE (n=1,855), the treatment difference was negative 0.06 points (95% CI: negative 0.48 to 0.36; p=0.7727). Semaglutide patients worsened by 2.2 points. Placebo patients worsened by 2.2 points. That is not a typo. The drug did literally nothing on the primary endpoint.

In EVOKE+ (n=1,953), the difference was 0.15 points (95% CI: negative 0.24 to 0.54; p=0.4604). Semaglutide: 2.1 points. Placebo: 2.0 points. The point estimate actually favored placebo, though the difference does not reach statistical significance.

The pooled time-to-dementia analysis across both trials produced a hazard ratio of 0.96 (95% CI: 0.86 to 1.06). A 4% reduction in progression risk that does not clear statistical significance across 3,808 patients is not a drug effect. It is noise.

The Biomarker Tease

Here is where it gets interesting. In a 199-patient CSF substudy, semaglutide produced nominally significant reductions of roughly 10% in several Alzheimer’s biomarkers. High-sensitivity C-reactive protein (hsCRP) dropped by 24% in EVOKE and 29% in EVOKE+, suggesting real anti-inflammatory activity in the brain. The drug is doing something biologically. It just is not doing enough to change the clinical trajectory.

This is the same pattern that killed dozens of Alzheimer’s candidates before Leqembi. Biomarker engagement without clinical benefit. The difference: Leqembi (lecanemab) showed a 27% slowing of cognitive decline on CDR-SB in its Phase 3 CLARITY AD trial, with a 0.45-point treatment difference at 18 months. Semaglutide showed 0.06 points at 24 months. Leqembi is a weak drug that works. Semaglutide is a strong drug that does not work for Alzheimer’s. (ClinicalTrials.gov NCT04777396)

Novo Nordisk itself called the program a “low likelihood of success” prospect going in. They were right. The 1-year extension period in both trials has been discontinued. There will be no FDA filing for semaglutide in Alzheimer’s.

Stock Performance: The Market Already Moved On

NVO closed at $48.77 on July 23, 2026, with a market capitalization of roughly $213 billion. The stock bottomed near $41 in early June following the Lancet publication, then recovered to $51.48 by mid-July before settling back to the $48 to $49 range. The EVOKE failure is already priced in.

The market reaction tells you something: investors never assigned much value to the Alzheimer’s program in the first place. Analysts at Morningstar pegged the Alzheimer’s opportunity as “only partly discounted” in Novo’s valuation. The stock’s 52-week range runs from $35.12 to $71.80. At $48.77, NVO trades at roughly 11.9x earnings. The consensus analyst price target sits at $57.92, implying 17% upside.

That 17% upside comes entirely from the core GLP-1 franchise: Ozempic, Wegovy, and the upcoming oral semaglutide launch for obesity. Alzheimer’s was never in the bull case for most analysts. It was optionality. That optionality is now zero.

The Competitive Picture

Novo Nordisk’s real threat is not a failed Alzheimer’s trial. It is Eli Lilly.

Lilly’s retatrutide is in Phase 3 for obesity with retatrutide TRIUMPH-2 and TRIUMPH-3 weight loss data in the TRIUMPH trials. Orforglipron, Lilly’s oral GLP-1, could reach the market by 2027 and directly compete with oral semaglutide. Novo’s pipeline outside GLP-1 is thin: Mim8 for hemophilia A has a PDUFA on July 29, and CagriSema (cagrilintide + semaglutide) is in Phase 3 for obesity with REDEFINE data expected in late 2026. Beyond those, the cupboard is bare.

The GLP-1 market is projected to reach $100 billion by 2030. Novo and Lilly split that roughly 50/50 today. But Lilly is gaining share. Mounjaro and Zepbound (tirzepatide) are outselling Ozempic and Wegovy in new prescriptions in the U.S. Retatrutide could extend Lilly’s lead further. Novo needs CagriSema to deliver differentiated efficacy. If it does not, the 11.9x earnings multiple starts looking expensive rather than cheap.

Meanwhile, Biogen’s Leqembi is the only approved disease-modifying Alzheimer’s therapy. Eisai guides roughly $900 million in Leqembi sales for fiscal 2026. That is a fraction of what semaglutide could have captured if EVOKE had succeeded. The Alzheimer’s market is still wide open, but Novo is no longer in it.

What the Biomarker Data Means for the Field

The EVOKE biomarker substudy showed that semaglutide reduces neuroinflammation (hsCRP down 24 to 29%) and produces modest reductions in CSF Alzheimer’s biomarkers. But every clinical endpoint was negative: CDR-SB, ADCS-ADL-MCI, and time to dementia progression. The hazard ratio for time to dementia was 0.96 with a confidence interval crossing 1.0. Neurofilament light, a marker of neuronal damage, actually increased by 5% in EVOKE+. Glial fibrillary acidic protein (GFAP), an astrocyte activation marker, rose 4% in both trials. These are not the biomarker signatures of a drug protecting neurons.

This is not a case where the trial was underpowered. Novo enrolled 3,808 patients across two trials. That is one of the largest Alzheimer’s trial programs ever conducted. The drug simply does not slow cognitive decline enough to matter clinically. Observational data from electronic health records had shown a 67% reduction in Alzheimer’s risk for semaglutide-treated diabetes patients (HR 0.33 versus insulin). But observational data reflects selection bias: patients prescribed semaglutide are typically younger, healthier, and earlier in their disease trajectory. Randomization stripped that bias away, and the effect vanished.

The GLP-1 brain hypothesis is not entirely dead. Novo is still running Parkinson’s trials with semaglutide. But the EVOKE failure makes it harder to justify those programs. If a drug cannot slow Alzheimer’s progression in 3,808 patients over 104 weeks despite measurable biomarker changes, the mechanism may not be potent enough for neurodegeneration. The anti-inflammatory effect is real but insufficient. Neurodegeneration may require more targeted intervention than a metabolic receptor agonist can provide.

The broader lesson for biotech investors: biomarker engagement without clinical benefit is the most expensive trap in neuroscience drug development. The pattern repeats. Drug hits the target. Biomarkers move. Patients do not improve. The drug fails. Semaglutide is just the latest and largest example.

The Risk

The specific risk for NVO shareholders is not Alzheimer’s. It is CagriSema. CagriSema (cagrilintide plus semaglutide) is Novo’s next-generation obesity therapy, and it is the only pipeline asset that can counter Lilly’s retatrutide. Phase 3 REDEFINE data is expected in late 2026. If CagriSema fails to show meaningful superiority over tirzepatide, Novo loses the GLP-1 arms race. At $213 billion in market cap, that scenario would take the stock to $35 or below.

The second risk is the Novo-Lilly lawsuit over GLP-1 advertising. Novo filed suit alleging Lilly uses outdated trial data to misleadingly claim superiority. This is a defensive move that signals Novo is losing the messaging war. Lawsuits do not win market share. Better drugs do.

Verdict

At $48.77, NVO is a hold. The EVOKE failure removed a pipeline scenario worth perhaps $10 to $15 billion in optionality, but the market has already absorbed that loss. The core GLP-1 franchise generates $20+ billion in annual revenue and growing. The 11.9x earnings multiple is reasonable for a company with Novo’s cash flows.

But the upside is capped. The consensus target of $57.92 assumes CagriSema delivers and oral semaglutide launches successfully. If both happen, NVO reaches $58. If CagriSema underwhelms, NVO tests $40. The risk/reward at $48.77 is roughly 1.2 to 1: 17% upside versus 14% downside. That is not enough to justify a new position.

I would hold NVO if I owned it. I would not add. The Alzheimer’s story is dead. The GLP-1 war with Lilly is the real fight. Novo needs CagriSema to win that fight. Until REDEFINE data arrives, there is no catalyst to move the stock meaningfully higher.